209 related articles for article (PubMed ID: 24141294)
21. Hydroxyurea and sickle cell anemia: effect on quality of life.
Ballas SK; Barton FB; Waclawiw MA; Swerdlow P; Eckman JR; Pegelow CH; Koshy M; Barton BA; Bonds DR
Health Qual Life Outcomes; 2006 Aug; 4():59. PubMed ID: 16942629
[TBL] [Abstract][Full Text] [Related]
22. Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective.
Nnebe-Agumadu U; Adebayo I; Erigbuem I; James E; Kumode E; Nnodu O; Adekile A
Pediatr Blood Cancer; 2021 Jun; 68(6):e28969. PubMed ID: 33788390
[TBL] [Abstract][Full Text] [Related]
23. Effects of hydroxyurea on blood rheology in sickle cell anemia: A two-years follow-up study.
Lemonne N; Möckesch B; Charlot K; Garnier Y; Waltz X; Lamarre Y; Antoine-Jonville S; Etienne-Julan M; Hardy-Dessources MD; Romana M; Connes P
Clin Hemorheol Microcirc; 2017; 67(2):141-148. PubMed ID: 28759962
[TBL] [Abstract][Full Text] [Related]
24. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
[TBL] [Abstract][Full Text] [Related]
25. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
Voskaridou E; Christoulas D; Bilalis A; Plata E; Varvagiannis K; Stamatopoulos G; Sinopoulou K; Balassopoulou A; Loukopoulos D; Terpos E
Blood; 2010 Mar; 115(12):2354-63. PubMed ID: 19903897
[TBL] [Abstract][Full Text] [Related]
26. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
27. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
[TBL] [Abstract][Full Text] [Related]
28. Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
Green NS; Barral S
Pediatr Res; 2014 Jan; 75(1-2):196-204. PubMed ID: 24252885
[TBL] [Abstract][Full Text] [Related]
29. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease.
Bachir D; Hulin A; Huet E; Habibi A; Nzouakou R; El Mahrab M; Astier A; Galacteros F
Hemoglobin; 2007; 31(4):417-25. PubMed ID: 17994375
[TBL] [Abstract][Full Text] [Related]
30. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
[TBL] [Abstract][Full Text] [Related]
31. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
Rogers ZR
Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
[TBL] [Abstract][Full Text] [Related]
32. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
33. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
34. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.
Saleh AW; Hillen HF; Duits AJ
Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885
[TBL] [Abstract][Full Text] [Related]
35. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Okam MM; Ebert BL
Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
[TBL] [Abstract][Full Text] [Related]
36. Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia.
Fitzhugh CD; Hsieh MM; Allen D; Coles WA; Seamon C; Ring M; Zhao X; Minniti CP; Rodgers GP; Schechter AN; Tisdale JF; Taylor JG
PLoS One; 2015; 10(11):e0141706. PubMed ID: 26576059
[TBL] [Abstract][Full Text] [Related]
37. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.
de Montalembert M; Belloy M; Bernaudin F; Gouraud F; Capdeville R; Mardini R; Philippe N; Jais JP; Bardakdjian J; Ducrocq R; Maier-Redelsperger M; Elion J; Labie D; Girot R
J Pediatr Hematol Oncol; 1997; 19(4):313-8. PubMed ID: 9256830
[TBL] [Abstract][Full Text] [Related]
38. Severity of Brazilian sickle cell disease patients: severity scores and feasibility of the Bayesian network model use.
Belini Junior E; Silva DG; Torres Lde S; Okumura JV; Lobo CL; Bonini-Domingos CR
Blood Cells Mol Dis; 2015 Apr; 54(4):321-7. PubMed ID: 25842370
[TBL] [Abstract][Full Text] [Related]
39. Hydroxyurea for the treatment of sickle cell disease.
Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S
Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478
[TBL] [Abstract][Full Text] [Related]
40. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
